rtki cpd has been researched along with N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, AJ; Cody, DR; Denny, WA; Fry, DW; Kraker, AJ; McMichael, A; Rewcastle, GW; Showalter, HD; Zhou, H | 1 |
| Caflisch, A; Dey, F; Huang, D; Kolb, P | 1 |
2 other study(ies) available for rtki cpd and N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine
| Article | Year |
|---|---|
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Topics: Aniline Compounds; Binding Sites; Blotting, Western; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Kinetics; Molecular Conformation; Molecular Structure; Phosphorylation; Protein Binding; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |
Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model.
Topics: Humans; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Quantitative Structure-Activity Relationship; Static Electricity; Thermodynamics | 2008 |